Acurx Pharmaceuticals (NASDAQ:ACXP) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Acurx Pharmaceuticals (NASDAQ:ACXP) from a sell rating to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Price Performance

ACXP opened at $1.92 on Friday. The company has a market cap of $5.49 million, a price-to-earnings ratio of -0.47 and a beta of -2.09. The firm has a 50 day simple moving average of $3.10 and a 200 day simple moving average of $3.20. Acurx Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). As a group, analysts expect that Acurx Pharmaceuticals will post -1.94 EPS for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Large investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter valued at approximately $27,000. Armistice Capital LLC bought a new stake in Acurx Pharmaceuticals in the second quarter valued at approximately $551,000. Millennium Management LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter valued at approximately $103,000. Finally, Geode Capital Management LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter valued at approximately $31,000. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).